Relevant Pharmacologic Interactions in the Concurrent Management of Brain Tumor-related Epilepsy and Venous Thromboembolism: a Systematic Review

Overview

Journal J Neurooncol

Publisher Springer

Date 2022 Mar 21

PMID 35312937

Authors

David Gritsch

L Nicolas Gonzalez Castro

Affiliations

Soon will be listed here.

Abstract

Introduction: Co-administration of direct oral anticoagulants (DOACs) with antiepileptic drugs (AEDs) is increasingly common in brain tumor patients. We therefore performed a systematic review of the current evidence for potential drug interactions between DOACs and AEDs in this patient population.

Methods: We conducted a systematic review of the literature via PubMed according to PRISMA guidelines (last accessed December 15, 2021). Included were clinical studies and case reports, written in English language and published between 2010 and 2021, that investigated concurrent clinical use of AEDs with DOACs for any indication. Non-English articles, articles not related to our research question, review articles and commentaries were excluded. Full-text articles were evaluated for possible confounding factors and results were summarized using a data table highlighting the key characteristics of each article.

Results: We identified a total of 122 unique articles, of which 27 were deemed relevant to our research question. Of these, 8 articles were clinical studies (n = 295,415 patients) and 19 were case reports (n = 25 patients). Only 3 clinical studies and 2 case reports reported interactions between AEDs and DOACs in patients with active cancer and none reported interactions in patients with brain tumors.

Conclusion: We have identified low (class IV) level evidence of potential drug interactions between DOACs and AEDs. Even though there is no current report of interactions in brain tumor patients, neuro-oncology providers should be aware of the emerging evidence regarding drug interactions between DOACs and AEDs and take this into consideration when concurrently prescribing these to patients.

Citing Articles

Recurrent Glioblastoma: Ongoing Clinical Challenges and Future Prospects.

Pineda E, Domenech M, Hernandez A, Comas S, Balana C Onco Targets Ther. 2023; 16:71-86.

PMID: 36721854 PMC: 9884437. DOI: 10.2147/OTT.S366371.

References

Glantz M, Cole B, Forsyth P, Recht L, Wen P, Chamberlain M . Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000; 54(10):1886-93. DOI: 10.1212/wnl.54.10.1886. View

Walbert T, Harrison R, Schiff D, Avila E, Chen M, Kandula P . SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neuro Oncol. 2021; 23(11):1835-1844. PMC: 8563323. DOI: 10.1093/neuonc/noab152. View

Chang S, Messersmith H, Ahluwalia M, Andrews D, Brastianos P, Gaspar L . Anticonvulsant Prophylaxis and Steroid Use in Adults With Metastatic Brain Tumors: ASCO and SNO Endorsement of the Congress of Neurological Surgeons Guidelines. J Clin Oncol. 2019; 37(13):1130-1135. PMC: 7098828. DOI: 10.1200/JCO.18.02085. View

Young A, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C . Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol. 2018; 36(20):2017-2023. DOI: 10.1200/JCO.2018.78.8034. View

Connolly S, Crowther M, Eikelboom J, Gibson C, Curnutte J, Lawrence J . Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. N Engl J Med. 2019; 380(14):1326-1335. PMC: 6699827. DOI: 10.1056/NEJMoa1814051. View

Key N, Khorana A, Kuderer N, Bohlke K, Lee A, Arcelus J . Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2019; 38(5):496-520. DOI: 10.1200/JCO.19.01461. View

Farge D, Frere C, Connors J, Ay C, Khorana A, Munoz A . 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019; 20(10):e566-e581. DOI: 10.1016/S1470-2045(19)30336-5. View

Streiff M, Abutalib S, Farge D, Murphy M, Connors J, Piazza G . Update on Guidelines for the Management of Cancer-Associated Thrombosis. Oncologist. 2020; 26(1):e24-e40. PMC: 7794170. DOI: 10.1002/onco.13596. View

Taha M, Li W, Schmidt C, Gonzalez-Castellon M, Taraschenko O . The interactions between anticonvulsants and non-vitamin K antagonist oral anticoagulant agents: A systematic review. Epilepsy Res. 2020; 162:106304. DOI: 10.1016/j.eplepsyres.2020.106304. View

10.

Galgani A, Palleria C, Iannone L, De Sarro G, Giorgi F, Maschio M . Pharmacokinetic Interactions of Clinical Interest Between Direct Oral Anticoagulants and Antiepileptic Drugs. Front Neurol. 2018; 9:1067. PMC: 6292857. DOI: 10.3389/fneur.2018.01067. View

11.

Stollberger C, Finsterer J . Interactions between non-vitamin K oral anticoagulants and antiepileptic drugs. Epilepsy Res. 2016; 126:98-101. DOI: 10.1016/j.eplepsyres.2016.06.003. View

12.

van Breemen M, Wilms E, Vecht C . Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol. 2007; 6(5):421-30. DOI: 10.1016/S1474-4422(07)70103-5. View

13.

Soffietti R, Baumert B, Bello L, Deimling A, Duffau H, Frenay M . Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol. 2010; 17(9):1124-1133. DOI: 10.1111/j.1468-1331.2010.03151.x. View

14.

Carneiro F, Amorim R, Carneiro M, Castro T, Vianna L, Takano G . P16 as a marker of carcinoma in effusions and peritoneal washing. BMC Cancer. 2020; 20(1):225. PMC: 7076945. DOI: 10.1186/s12885-020-6670-5. View

15.

Streiff M, Ye X, Kickler T, Desideri S, Jani J, Fisher J . A prospective multicenter study of venous thromboembolism in patients with newly-diagnosed high-grade glioma: hazard rate and risk factors. J Neurooncol. 2015; 124(2):299-305. PMC: 4659392. DOI: 10.1007/s11060-015-1840-z. View

16.

Marras L, Geerts W, Perry J . The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer. 2000; 89(3):640-6. DOI: 10.1002/1097-0142(20000801)89:3<640::aid-cncr20>3.0.co;2-e. View

17.

Raskob G, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D . Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2017; 378(7):615-624. DOI: 10.1056/NEJMoa1711948. View

18.

Swartz A, Drappatz J . Safety of Direct Oral Anticoagulants in Central Nervous System Malignancies. Oncologist. 2021; 26(5):427-432. PMC: 8100560. DOI: 10.1002/onco.13698. View

19.

Elmeliegy M, Vourvahis M, Guo C, Wang D . Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug-Drug Interaction Studies. Clin Pharmacokinet. 2020; 59(6):699-714. PMC: 7292822. DOI: 10.1007/s40262-020-00867-1. View

20.

Perucca E . Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 2006; 61(3):246-55. PMC: 1885026. DOI: 10.1111/j.1365-2125.2005.02529.x. View